NCT05567796
REDEFINE — CagriSema in obesity
Phase Phase 3
Status Active, not recruiting
Indication Obesity
Enrollment 3,417
Last updated:Jul 15, 2026Source:ClinicalTrials.govVerified:NCT ID verified against public registryData provider:ClinicalTrials.gov API v2
Overview
- NCT ID
- NCT05567796
- Phase
- Phase 3
- Status
- Active, not recruiting
- Indication
- Obesity
- Primary completion
- 1/1/2026
- Enrollment (planned/actual)
- 3,417
- Sponsor
- Novo Nordisk
- Peptide
- Cagrilintide
Peptide under study
Cagrilintide
Long-acting amylin analog · Phase 3